Klin Farmakol Farm. 2023;37(3):93-101 | DOI: 10.36290/far.2023.017

Individual pharmacokinetic modelling and therapeutic drug monitoring

Blanka Kořístková1, 2
1 Ústav klinické farmakologie, Lékařská fakulta, Ostravská univerzita, Ostrava
2 Oddělení klinické farmakologie, Ústav laboratorní medicíny, Fakultní nemocnice Ostrava

Therapeutic drug monitoring allows the adjustment of the patient's dosage based on the drug concentration. Pharmacokinetic modelling software enables to predict the concentrations with regular and irregular dosing, with non-standard sampling times, before reaching a steady state or with changing function of elimination organs, in particular kidneys. Unexpected results can be caused by a sampling error (esp. when sample was taken from the same site as the drug was administered, or sampling from a central venous catheter), an incomplete drug history during dosage changes before sampling, missing information on the use of a loading dose, or a drug interaction. A specific case is the administration of the drug to dialysis patients, where a significant dose reduction is necessary in intermittent dialysis, while in continuous dialysis the dosage is proportional to serum creatinine values. To correctly interpret the results, correct and complete input data of the patient and, in particular, a full dose history are necessary.

Keywords: PK/PD modelling, pharmacokinetic analysis, Mw\\Pharm, TDM.

Accepted: October 12, 2023; Published: October 13, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kořístková B. Individual pharmacokinetic modelling and therapeutic drug monitoring. Klin Farmakol Farm. 2023;37(3):93-101. doi: 10.36290/far.2023.017.
Download citation

References

  1. Kacirova I, Grundmann M. Terapeutické monitorování léčiv - review. Klin Farmakol Farm. 2020;34(2):47-55. Go to original source...
  2. Avent ML, Rogers BA, Optimising antimicrobial therapy through the use of Bayesian dosing programs, Int. J. Clin. Pharm. 2019;41:1121-1130. Go to original source... Go to PubMed...
  3. Mw\\Pharm 3:30 a MediWare Product in cooperation with: University Center for Pharmacy, Dept of Pharmacokinetics and Drug Delivery, University of Groningen, The Netherlands. Supervision DKF Meier, JH Proost. MediWare.
  4. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: reviwe of current algorithms. The Drug Monit. 2001;23(2):100-114. Go to original source... Go to PubMed...
  5. Koristkova B, Grundmann M, Brozmanova H, et al. Validation of sparse sampling strategies for estimating cyclosporine A area under the concentration-time curve when analyzed with specific RIA and HPLC method. Ther Drug Monit. 2010;32(5):586-593. Go to original source... Go to PubMed...
  6. Koristkova B, Vavreckova E, Schön K, et al. Comparison of MwPharm 3.30 and MwPharm ++ (Windows version) software for PK/PD monitoring of vancomycin: A priori modeling. Int J Clin Pharmacol Ther. 2021;60(7):299-305. Go to original source... Go to PubMed...
  7. Schön K, Koristkova B, Kacirova I, et al. Comparison of Mw\\Pharm 3.30 and Mw\\Pharm ++, a Windows version of pharmacokinetic software for PK/PD monitoring of vancomycin. Part 1: A-posteriori modelling. Comput Methods Programs Biomed. 2022;214:106552. Go to original source... Go to PubMed...
  8. Aonuma K, Shiga T, Atarashi H, et al. Guidelines for therapeutic drug monitoring of cardiovascular drugs clinical use of blood drug concentration monitoring (JCS 2015) - Digest version. Circ J. 2017;24(4):581-612. Go to original source... Go to PubMed...
  9. SPC Edicin, sp.zn. sukls25384/2021, datum revize 3. 2. 2021. Available from: www.sukl.cz.
  10. SPC Amikacin Fresenius Kabi, sp. zn. sukls112236/2023, datum revize 4.5.23. Available from: www.sukl.cz.
  11. SPC Gentamicin B. Braun, Sp. zn. sukls25392/2023 datum revize 9.3.23. Available from: www.sukl.cz.
  12. Potter JM, Donnelly A. Carbamazepine-10,11-epoxide in therapeutic drug monitoring. Ther Drug Monit. 1998;20(6): 652-657. Go to original source... Go to PubMed...
  13. Kořístková B, Grundmann M, Kacířová I, Brozmanová H. The effect of valproic acid on plasma level of carbamazepine and carbamazepine-10, 11-epoxide in long-term treatment with slow-release drug formulations in pediatric patients; the importance of TDM. Klin farmakol farm. 2021;35(2):49-53. Go to original source...
  14. Rybak MJ, Le J, Lodise T, et al. Executive summary: therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review of the American society of health-system pharmacists, the Infectious diseases society of America, the Pediatric infectious diseases society, and the Society of infectious diseases pharmacists. Pharmacotherapy. 2020;40(4)363-367. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.